Biogen stock gains 1.56 percent as litifilimab data reach Week 52

Published on 10/05/2026 at 21:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Biogen stock trades at USD 223.32 on October 5 after litifilimab reached a 27.2 percent Week 52 response rate. Q2 revenue rose 3.4 percent to USD 2.736 billion.

Architektur-Render eines modernen Biotech-Campus mit geschwungener Glasfassade und Wasserelement — Biogen Inc. modernes Biotech-Hauptquartier als futuristisches gläsernes Architektur-Render mit Grünanlagen ISIN US09062X1037, Illustration mit AI erstellt.

Biogen stock (ISIN US09062X1037) was trading at USD 223.32 on Nasdaq at 3:29 p.m. ET on October 5, 2026, up 1.56 percent from the USD 219.88 prior close. The company’s latest clinical update showed litifilimab improving key cutaneous lupus measures through Week 52, giving investors a new pipeline data point ahead of the next earnings report.

Litifilimab reaches a longer-term test

According to Biogen on October 2, 2026, 27.2 percent of participants treated with litifilimab from the start of the AMETHYST Phase 2 study achieved clear or near-clear skin at Week 52. The comparable Week 24 result was 19.0 percent, a gain of 8.2 percentage points over the longer observation period.

The CLASI-70 measure also improved: 28.8 percent of participants reached at least a 70 percent reduction in disease activity at Week 52, compared with 21.7 percent at Week 24. The Phase 2 portion enrolled 93 adults, while the Phase 3 portion remains blinded and is expected to produce results in the first half of 2027, according to Biogen.

Revenue grows while GAAP profit falls

Biogen’s second-quarter 2026 revenue rose 3.4 percent year over year to USD 2.736 billion, while GAAP diluted EPS was USD 0.66, down from USD 4.33 in the comparable quarter. The figures come from the standardized quarterly statements for the period ended June 30, 2026.

On the adjusted basis reported by MarketBeat, second-quarter EPS was USD 3.60 against a USD 2.94 consensus estimate, a USD 0.66 beat. Biogen set 2026 guidance at USD 12.00 to USD 13.00 in EPS, showing how acquisition-related costs weigh more heavily on reported earnings than on the adjusted measure.

Analysts see limited target upside

Needham analyst Ami Fadia reiterated a Buy rating and set a USD 256.00 price target, as Markets Insider reported on October 2, 2026. The same report cited a Moderate Buy consensus and a USD 238.22 average target, implying the target is 6.7 percent above the USD 223.32 intraday price.

Biogen stock holds above USD 220

Biogen stock was trading between USD 218.22 and USD 223.48 on Nasdaq on October 5, 2026. Its 52-week range was USD 138.00 to USD 230.49, while market capitalization stood at USD 33.0 billion and volume reached 495,679 shares.